receptor EP4

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 9175080
APP PUB NO 20130197199A1
SERIAL NO

13876763

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

It is an object of the present invention to provide an antibody that binds to a human PGE2 receptor subtype EP4 and inhibits the function of EP4, or a functional fragment thereof. It is another object of the present invention to provide a medicament comprising the aforementioned antibody or a functional fragment thereof. Mice were immunized with the human PGE2 receptor subtype EP4, and a monoclonal antibody that suppresses the intracellular cAMP level increase induced by EP4 was screened. In addition, the CDR sequences of the obtained monoclonal antibody were determined.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
NB HEALTH LABORATORY CO LTD12-2 KITA 21-JOU NISHI KITA-KU SAPPORO-SHI HOKKAIDO 0010021 ?0010021

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Shimizu, Tomoko Sapporo, JP 20 54
Sugimoto, Yukihiko Kumamoto, JP 17 119
Takayama, Kiyoshi Sapporo, JP 16 24
Urushibata, Yuji Sapporo, JP 7 4

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
11.5 Year Payment $7400.00 $3700.00 $1850.00 May 3, 2027
Fee Large entity fee small entity fee micro entity fee
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00